Acute lymphoblastic leukaemia

The Lancet

Volumn 371, Issue 9617, 2008, Pages 1030-1043

  Pui, Ching Hon ^a   Robison, Leslie L ^a   Look, A Thomas ^b  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; ANTHRACYCLINE; ANTILEUKEMIC AGENT; ASPARAGINASE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; DASATINIB; DEXAMETHASONE; HYDROCORTISONE; IMATINIB; MERCAPTOPURINE; METHOTREXATE; NILOTINIB; PREDNISOLONE; PREDNISONE; TIOGUANINE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLOOD TOXICITY; CANCER RISK; CANCER SURVIVAL; CHILD HEALTH; CLINICAL TRIAL; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG INTOXICATION; DRUG MEGADOSE; DRUG POTENTIATION; DRUG TARGETING; HUMAN; LYMPHOID CELL; MEDICAL RESEARCH; MOLECULAR MECHANICS; NONHUMAN; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; STEM CELL; THROMBOCYTOPENIA; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 40749150603     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(08)60457-2     Document Type: Review

References (171)

1. Pui C., and Evans W. Treatment of acute lymphoblastic leukemia. N Engl J Med 354 (2006) 166-178
2. Silverman L., Gelber R., Dalton V., et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood 97 (2001) 1211-1218
3. Bürger B., Zimmermann M., Mann G., et al. Diagnostic cerebrospinal fluid examination in children with acute lymphoblastic leukemia: significance of low leukocyte counts with blasts or traumatic lumbar puncture. J Clin Oncol 21 (2003) 179-181
4. Vitale A., Guarini A., Chiaretti S., and Foá R. The changing scene of adult acute lymphoblastic leukemia. Curr Opin Oncol 18 (2006) 652-659
5. Román-Gómez J., Cordeu L., Agirre X., et al. Epigenetic regulation of Wnt-signaling pathway in acute lymphoblastic leukemia. Blood 109 (2007) 3462-3469
6. Pui C., Relling M., and Downing J. Acute lymphoblastic leukemia. N Engl J Med 350 (2004) 1535-1548
7. Evans W., and Relling M. Moving towards individualized medicine with pharmacogenomics. Nature 429 (2004) 464-468
8. Hjalgrim L., Westergaard T., Rostgaard K., et al. Birth weight as a risk factor for childhood leukemia: a meta-analysis of 18 epidemiologic studies. Am J Epidemiol 158 (2003) 724-735
9. Ahlbom A., Day N., Feychting M., et al. A pooled analysis of magnetic fields and childhood leukaemia. Br J Cancer 83 (2000) 692-698
10. Buffler P., Kwan M., Reynolds P., and Urayama K. Environmental and genetic risk factors for childhood leukemia: appraising the evidence. Cancer Invest 23 (2005) 60-75
11. Kinlen L. Infections and immune factors in cancer: the role of epidemiology. Oncogene 23 (2004) 6341-6348
12. Greaves M. Infection, immune responses and the aetiology of childhood leukaemia. Nat Rev Cancer 6 (2006) 193-203
13. Wiemels J., Cazzaniga G., Daniotti M., et al. Prenatal origin of acute lymphoblastic leukaemia in children. Lancet 354 (1999) 1499-1503
14. Maia A., van der Velden V., Harrison C., et al. Prenatal origin of hyperdiploid acute lymphoblastic leukemia in identical twins. Leukemia 17 (2003) 2002-2006
15. Hong D., Gupta R., Ancliff O., et al. Initiating and cancer-propagating cells in TEL-AML1-associated childhood leukemia. Science 319 (2008) 336-339
16. Mori H., Colman S., Xiao Z., et al. Chromosome translocations and covert leukemic clones are generated during normal fetal development. Proc Natl Acad Sci USA 99 (2002) 8242-8247
17. Greaves M., and Wiemels J. Origins of chromosome translocations in childhood leukaemia. Nat Rev Cancer 3 (2003) 639-649
18. Lanciotti M., Dufour C., Corral L., et al. Genetic polymorphism of NAD(P)H: quinone oxidoreductase is associated with an increased risk of infant acute lymphoblastic leukemia without MLL gene rearrangements. Leukemia 19 (2005) 214-216
19. Krajinovic M., Labuda D., and Sinnett D. Glutathione S-transferase P1 genetic polymorphisms and susceptibility to childhood acute lymphoblastic leukaemia. Pharmacogenetics 12 (2002) 655-658
20. Skibola C., Smith M., Kane E., et al. Polymorphisms in the methylenetetrahydrofolate reductase gene are associated with susceptibility to acute leukemia in adults. Proc Natl Acad Sci USA 96 (1999) 12810-12815
21. Skibola C., Smith M., Hubbard A., et al. Polymorphisms in the thymidylate synthase and serine hydroxymethyltransferase genes and risk of adult acute lymphocytic leukemia. Blood 99 (2002) 3786-3791
22. 1/S checkpoint regulators and their impact on the susceptibility to childhood leukemia. Blood 109 (2007) 683-692
23. Gast A., Bermejo J., Flohr T., et al. Folate metabolic gene polymorphisms and childhood acute lymphoblastic leukemia: a case-control study. Leukemia 21 (2007) 320-325
24. Spector L., Xie Y., Robison L., et al. Maternal diet and infant leukemia: the DNA topoisomerase II inhibitor hypothesis: a report from the Children's Oncology Group. Cancer Epidemiol Biomarkers Prev 14 (2005) 651-655
25. Pui C., and Relling M. Topoisomerase II inhibitor-related acute myeloid leukaemia. Br J Haematol 109 (2000) 13-23
26. Pui C., Campana D., and Evans W. Childhood acute lymphoblastic leukaemia: current status and future perspectives. Lancet Oncol 2 (2001) 597-607
27. Biondi A., Cimino G., Pieters R., and Pui C. Biological and therapeutic aspects of infant leukemia. Blood 96 (2000) 24-33
28. Armstrong S., and Look A. Molecular genetics of acute lymphoblastic leukemia. J Clin Oncol 23 (2005) 6306-6315
29. Wang J., and Dick J. Cancer stem cells: lessons from leukemia. Trends Cell Biol 15 (2005) 494-501
30. Ferrando A., Neuberg D., Staunton J., et al. Gene expression define novel oncogenic pathways in T-cell acute lymphoblastic leukemia. Cancer Cell 1 (2002) 75-87
31. Weinstein I., and Joe A. Mechanisms of disease: oncogene addiction-a rationale for molecular targeting in cancer therapy. Nat Clin Pract Oncol 3 (2006) 448-457
32. Yeoh E., Ross M., Shurtleff S., et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 1 (2002) 133-143
33. Armstrong S., Staunton J., Silverman L., et al. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet 30 (2002) 41-47
34. Ferrando A., Armstrong S., Neuberg D., et al. Gene expression signatures in MLL-rearranged T-lineage and B-precursor acute leukemias: dominance of HOX dysregulation. Blood 102 (2003) 262-268
35. Lu J., Getz G., Miska E., et al. MicroRNA expression profiles classify human cancers. Nature 435 (2005) 834-838
36. Hock H., Meade E., Medeiros S., et al. Tel/Etv6 is an essential and selective regulator of adult hematopoietic stem cell survival. Genes Dev 18 (2004) 2336-2341
37. Okuda T., van Deursen J., Hiebert S., Grosveld G., and Downing J. AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell 84 (1996) 321-330
38. Wang Q., Stacy T., Binder M., et al. Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis. Proc Natl Acad Sci USA 93 (1996) 3444-3449
39. Ren R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer 5 (2005) 172-183
40. Druker B. Imatinib as a paradigm of targeted therapies. Adv Cancer Res 91 (2004) 1-30
41. Weng A., Ferrando A., Lee W., et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 306 (2004) 269-271
42. Grabher C., von Boehmer H., and Look A. Notch 1 activation in the molecular pathogenesis of T-cell acute lymphoblastic leukaemia. Nat Rev Cancer 6 (2006) 347-359
43. Weng A., Millholland J., Yashiro-Ohtani Y., et al. c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma. Genes Dev 20 (2006) 2096-2109
44. Palomero T., Lim W., Odom D., et al. NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth. Proc Natl Acad Sci USA 103 (2006) 18261-18266
45. Sharma V., Calvo J., Draheim K., et al. Notch1 contributes to mouse T-cell leukemia by directly inducing the expression of c-myc. Mol Cell Biol 26 (2006) 8022-8031
46. Hoemann C., Beaulieu N., Girard L., Rebai N., and Jolicoeur P. Two distinct Notch1 mutant alleles are involved in the induction of T-cell leukemia in c-myc transgenic mice. Mol Cell Biol 20 (2000) 3831-3842
47. Wong G., Manfra D., Poulet F., et al. Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem 279 (2004) 12876-12882
48. Mullighan C., Goorha S., Radtke I., et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 446 (2007) 758-764
49. Van Dyke T., and Jacks T. Cancer modeling in the modern era: progress and challenges. Cell 108 (2002) 135-144
50. O'Neil J., Shank J., Cusson N., Murre C., and Kelliher M. TAL1/SCL induces leukemia by inhibiting the transcriptional activity of E47/HEB. Cancer Cell 5 (2004) 587-596
51. Eischen C., Weber J., Roussel M., Sherr C., and Cleveland J. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev 13 (1999) 2658-2669
52. Dupuy A., Akagi K., Largaespada D., Copeland N., and Jenkins N. Mammalian mutagenesis using a highly mobile somatic Sleeping Beauty transposon system. Nature 436 (2005) 221-226
53. Amatruda J., Shepard J., Stern H., and Zon L. Zebrafish as a cancer model system. Cancer Cell 1 (2002) 229-231
54. Langenau D., Traver D., Ferrando A., et al. Myc-induced T cell leukemia in transgenic zebrafish. Science 299 (2003) 887-890
55. Langenau D., Feng H., Berghmans S., et al. Cre/lox-regulated transgenic zebrafish model with conditional myc-induced T cell acute lymphoblastic leukemia. Proc Natl Acad Sci USA 102 (2005) 6068-6073
56. Sabaawy H., Azuma M., Embree L., et al. TEL-AML1 transgenic zebrafish model of precursor B cell acute lymphoblastic leukemia. Proc Natl Acad Sci USA 103 (2006) 15166-15171
57. Croce C. Oncogenes and cancer. N Engl J Med 358 (2008) 502-511
58. Pui C., and Evans W. Acute lymphoblastic leukemia. N Engl J Med 339 (1998) 605-615
59. Mi S., Lu J., and Sun M. MicroRNA expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemia. Proc Natl Acad Sci USA 104 (2007) 19971-19976
60. Kawamata N., Ogawa S., Zimmermann M., et al. Molecular allelokaryotyping of pediatric acute lymphoblastic leukemias by high-resolution single nucleotide polymorphism oligonucleotide genomic microarray. Blood 111 (2008) 776-784
61. Tissing W., den Boer M., Meijerink J., et al. Genomewide identification of prednisolone-responsive gene in acute lymphoblastic leukemia cells. Blood 109 (2007) 3929-3935
62. Kishi S., Cheng C., French D., et al. Ancestry and pharmacogenetics of antileukemic drug toxicity. Blood 109 (2007) 4151-4157
63. Rocha J., Cheng C., Liu W., et al. Pharmacogenetics of outcome in children with acute lymphoblastic leukemia. Blood 105 (2005) 4752-4758
64. Relling M., Pui C., Cheng C., and Evans W. Thiopurine methyltransferase in acute lymphoblastic leukemia. Blood 107 (2006) 843-844
65. Stanulla M., Schaeffeler E., Flohr T., et al. Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia. JAMA 293 (2005) 1485-1489
66. Relling M., Rubnitz J., Rivera G., et al. High incidence of secondary brain tumours after radiotherapy and antimetabolites. Lancet 354 (1999) 34-39
67. Evans W., Hon Y., Bongaars L., et al. Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. J Clin Oncol 19 (2001) 2293-2301
68. Boissel N., Auclerc M., Lhéritier V., et al. Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol 21 (2003) 774-780
69. de Bont J., Holt B., Dekker A., et al. Significant difference in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric vs adult protocols in the Netherlands. Leukemia 18 (2004) 2032-2035
70. Ramanujachar R., Richards S., Hann I., et al. Adolescents with acute lymphoblastic leukaemia: outcome on UK national paediatric (ALL97) and adult (UKALLXII/E2993) trials. Pediatr Blood Cancer 48 (2007) 254-261
71. Hallböök H., Gustafsson G., Smedmyr B., et al. Treatment outcome in young adults and children >10 years of age with acute lymphoblastic leukemia in Sweden: a comparison between a pediatric protocol and an adult protocol. Cancer 107 (2006) 1551-1561
72. Barry E., DeAngelo D., Neuberg D., et al. Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols. J Clin Oncol 25 (2007) 813-819
73. Hilden J., Dinndorf P., Meerbaum S., et al. Analysis of prognostic factors of acute lymphoblastic leukemia in infants: report on CCG 1953 from the Children's Oncology Group. Blood 108 (2006) 441-451
74. Pieters R., Schrappe M., De Lorenzo P., et al. A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial.l. Lancet 370 (2007) 240-250
75. Larson R. Management of acute lymphoblastic leukemia in older patients. Semin Hematol 43 (2006) 126-133
76. Landau H., and Lamanna N. Clinical manifestations and treatment of newly diagnosed acute lymphoblastic leukemia in adults. Curr Hematol Malig Rep 1 (2006) 171-179
77. Pui C.-H. Central nervous system disease in acute lymphoblastic leukemia: prophylaxis and treatment. Hematology Am Soc Hematol Educ Program (2006) 142-146
78. Lowe E., Pui C., Hancock M., et al. Early complications in children with acute lymphoblastic leukemia presenting with hyperleukocytosis. Pediatr Blood Cancer 45 (2005) 10-15
79. Kadan-Lottick N., Ness K., Bhata S., and Gurney J. Survival variability by race and ethnicity in childhood acute lymphoblastic leukemia. JAMA 290 (2003) 2008-2014
80. Pui C., Sandlund J., Pei D., et al. Results of therapy for acute lymphoblastic leukemia in black and white children. JAMA 290 (2003) 2001-2007
81. Pui C., Sandlund J., Pei D., et al. Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. Blood 104 (2004) 2690-2696
82. Butturini A., Dorey F., Lange B., et al. Obesity and outcome in pediatric acute lymphoblastic leukemia. J Clin Oncol 25 (2007) 2063-2069
83. Hijiya N., Panetta J., Zhou Y., et al. Body mass index does not influence pharmacokinetics or outcome of treatment in children with acute lymphoblastic leukemia. Blood 108 (2006) 3997-4002
84. Rowe J., Buck G., Burnett A., et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial-MRC UKALL XII/ECOG E2993. Blood 106 (2005) 3760-3767
85. Moorman A., Harrison C., Buck G., et al. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. Blood 109 (2007) 3189-3197
86. Nachman J., Heerema N., Sather H., et al. Outcome of treatment in children with hypodiploid acute lymphoblastic leukemia. Blood 110 (2007) 1112-1115
87. Schultz K., Pullen D., Sather H., et al. Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG). Blood 109 (2007) 926-935
88. Moorman A., Richards S., Robinson H., et al. Prognosis of children with acute lymphoblastic leukemia (ALL) and intrachromosomal amplification of chromosome 21 (iAMP21). Blood 109 (2007) 2327-2330
89. Arico M., Valsecchi M., Camitta B., et al. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med 342 (2000) 998-1006
90. Gleissner B., Gokbuget N., Bartram C., et al. Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial group and confirmed polymerase chain reaction analysis. Blood 99 (2002) 1536-1543
91. Mancini M., Scappaticci D., Cimino G., et al. A comprehensive genetic classification of adult acute lymphoblastic leukemia (ALL): analysis of the GIMEMA 0496 protocol. Blood 105 (2005) 3434-3441
92. Pui C., Gaynon P., Boyett J., et al. Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region. Lancet 359 (2002) 1909-1915
93. Gleissner B., Goekbuget N., Rieder H., et al. CD10- pre-B acute lymphoblastic leukemia (ALL) is a distinct high-risk subgroup of adult ALL associated with a high frequency of MLL aberrations: results of the German Multicenter Trials for Adult ALL (GMALL). Blood 106 (2005) 4054-4056
94. Breit S., Stanulla M., Flohr T., et al. Activating NOTCH1 mutations predict favorable early treatment response and long-term outcome in childhood precursor T-cell lymphoblastic leukemia. Blood 108 (2006) 1151-1157
95. Zhu Y., Zhao W., Fu J., et al. NOTCH1 mutations in T-cell acute lymphoblastic leukemia: prognostic significance and implication in multifactorial leukemogenesis. Clin Cancer Res 12 (2006) 3043-3049
96. Cheok M., Yang W., Pui C., et al. Treatment-specific changes in gene expression discriminate in vivo drug response in human leukemia cells. Nat Genet 34 (2003) 85-90
97. Zaza G., Cheok M., Yang M., et al. Gene expression and thioguanine nucleotide disposition in acute lymphoblastic leukemia after in vivo mercaptopurine treatment. Blood 106 (2005) 1778-1785
98. Kager L., Cheok M., Yang W., et al. Folate pathway gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexate pharmacodynamics. J Clin Invest 115 (2005) 110-117
99. Holleman A., Cheok M., den Boer M., et al. Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med 351 (2004) 533-542
100. Cheng Q., Yang W., Raimondi S., et al. Karyotypic abnormalities create discordance of germline genotype and cancer cell phenotypes. Nat Genet 37 (2005) 878-882
101. Panzer-Grümayer E., Schneider M., Panzer S., et al. Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia. Blood 95 (2000) 790-794
102. Dworzak M., Fröschl G., Printz D., et al. Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia. Blood 99 (2002) 1952-1958
103. Zhou J., Goldwasser M., Li A., et al. Quantitative analysis of minimal residual disease predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL Consortium Protocol 95-01. Blood 110 (2007) 1607-1611
104. Bruggemann M., Raff T., Flohr T., et al. Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood 107 (2006) 1116-1123
105. Chauvenet A., Martin P., Devidas M., et al. Antimetabolite therapy for lesser-risk B-lineage acute lymphoblastic leukemia of childhood: a report from Children's Oncology Group Study P9201. Blood 110 (2007) 1105-1111
106. Coustan-Smith E., Sancho J., Behm F., et al. Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia. Blood 100 (2002) 52-58
107. Raff T., Gökbüget N., Luschen S., et al. Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06/99 and 07/03 trials. Blood 109 (2007) 910-915
108. Coustan-Smith E., Ribeiro R., Stow P., et al. A simplified flow cytometric assay identifies children with acute lymphoblastic leukemia who have a superior clinical outcome. Blood 108 (2006) 97-102
109. Patte C., Auperin A., Michon J., and Behrendt H. The Société Française d'Oncologie Pédiatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood 97 (2001) 3370-3379
110. Woessmann W., Seidemann K., Mann G., et al. The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95. Blood 105 (2005) 948-958
111. Lee E., Petroni G., Schiffer C., et al. Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251. J Clin Oncol 19 (2001) 4014-4022
112. Yanada M., Takeuchi J., Sugiura I., et al. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol 24 (2006) 460-466
113. de Labarthe A., Rousselot P., Huguet-Rigal F., et al. Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study. Blood 109 (2007) 1408-1413
114. Delannoy A., Delabesse E., Lheritier V., et al. Imatinib and methylprednisolone alternated with chemotherapy improve the outcome of elderly patients with Philadelphia-positive acute lymphoblastic leukemia: results of the GRAALL AFR09 study. Leukemia 20 (2006) 1526-1532
115. Kantarjian H., Giles F., Wunderle L., et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 354 (2006) 2542-2551
116. Talpaz M., Shah N., Kantarjian H., et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 354 (2006) 2531-2541
117. Bostrom B., Sensel M., Sather H., et al. Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood 101 (2003) 3809-3817
118. Mitchell C., Richards S., Kinsey S., et al. Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trial. Br J Haematol 129 (2005) 734-745
119. Igarashi S., Manabe A., Ohara A., et al. No advantage of dexamethasone over prednisolone for the outcome of standard- and intermediate-risk childhood acute lymphoblastic leukemia in the Tokyo Children's Cancer Study Group L95-14 protocol. J Clin Oncol 23 (2005) 6489-6498
120. Pinheiro J., and Boos J. The best way to use asparaginase in childhood acute lymphoblastic leukemia: still to be defined?. Br J Haematol 125 (2004) 117-127
121. Duval M., Suciu S., Ferster A., et al. Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer-Children's Leukemia Group phase 3 trial. Blood 99 (2002) 2734-2739
122. Moghrabi A., Levy D., Asselin B., et al. Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Blood 109 (2007) 896-904
123. Avramis V., Sencer S., Periclou A., et al. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study. Blood 99 (2002) 1986-1994
124. Rizzari C., Citterio M., Zucchetti M., et al. A pharmacological study on pegylated asparaginase used in front-line treatment of children with acute lymphoblastic leukemia. Haematologica 91 (2006) 24-31
125. Douer D., Yampolsky H., Cohen L., et al. Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia. Blood 109 (2007) 2744-2750
126. Wetzler M., Sanford B., Kurtzberg J., et al. Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511. Blood 109 (2007) 4164-4167
127. Loh M., Goldwasser M., Silverman L., et al. Prospective analysis of TEL/AML1-positive patients treated on Dana-Farber Cancer Institute Consortium Protocol 95-01. Blood 107 (2006) 4508-4513
128. Nachman J., Sather H., Sensel M., et al. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. N Engl J Med 338 (1998) 1663-1671
129. Lange B., Bostrom B., Cherlow J., et al. Double-delayed intensification improves event-free survival for children with intermediate-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood 99 (2002) 825-833
130. Hoelzer D., and Gokbuget N. New approaches to lymphoblastic leukemia in adults: where do we go?. Semin Oncol 27 (2000) 540-559
131. Kantarjian H., Thomas D., O'Brien S., et al. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer 101 (2004) 2788-2801
132. Linker C., Damon L., Ries C., and Navarro W. Intensified and shortened cyclical chemotherapy for adult acute lymphoblastic leukemia. J Clin Oncol 20 (2002) 2464-2471
133. Schrappe M., Reiter A., Ludwig W., et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. Blood 95 (2000) 3310-3322
134. Pui C., Relling M., and Evans W. Is mega dose of methotrexate beneficial to patients with acute lymphoblastic leukemia?. Leuk Lymphoma 47 (2006) 2431-2432
135. 2) as central nervous system preventive therapy for childhood acute lymphoblastic leukemia: results of National Cancer Institute/Children's Cancer Group trials CCG-191P, CCG-134P, and CCG-144P. Leuk Lymphoma 47 (2006) 2488-2504
136. Skärby T., Anderson H., Heldrup J., et al. High leucovorin doses during high-dose methotrexate treatment may reduce the cure rate in childhood acute lymphoblastic leukemia. Leukemia 20 (2006) 1955-1962
137. Hunault M., Harousseau J., Delain M., et al. Better outcome of adult acute lymphoblastic leukemia after early genoidentical allogeneic bone marrow transplantation (BMT) than after late high-dose therapy and autologous BMT: a GOELAMS trial. Blood 104 (2004) 3028-3037
138. Ribera J., Ortega J., Oriol A., et al. Comparison of intensive chemotherapy, allogeneic or autologous stem cell transplantation as postremission treatment, for children with very high-risk acute lymphoblastic leukemia: PETHEMA ALL-93 Trial. J Clin Oncol 25 (2007) 16-24
139. Balduzzi A., Valsecchi M., Uderzo C., et al. Chemotherapy versus allogeneic transplantation for very-high-risk childhood acute lymphoblastic leukaemia in first complete remission: comparison by genetic randomisation in an international prospective study. Lancet 366 (2005) 635-642
140. Thomas X., Boiron J., Huguet F., et al. Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J Clin Oncol 22 (2004) 4075-4086
141. Schrauder A., Reiter A., Gadner H., et al. Superiority of allogeneic hematopoietic stem cell transplantation compared with chemotherapy alone in high-risk childhood T-cell acute lymphoblastic leukemia: results from ALL-BFM 90 and 95. J Clin Oncol 24 (2006) 5742-5749
142. Vey N., Thomas X., Picard C., et al. Allogeneic stem cell transplantation improves the outcome of adults with t(1;19)/E2A-PBX1 and t(4;11)/MLL-AF4 positive B-cell acute lymphoblastic leukemia: results of the prospective multicenter LALA-94 study. Leukemia 20 (2006) 2155-2161
143. Kosaka Y., Koh K., Kinukawa N., et al. Infant acute lymphoblastic leukemia with MLL gene rearrangements: outcome following intensive chemotherapy and hematopoietic stem cell transplantation. Blood 104 (2004) 3527-3534
144. Sanders J., Im H., Hoffmeister P., et al. Allogeneic hematopoietic cell transplantation for infants with acute lymphoblastic leukemia. Blood 105 (2005) 3749-3756
145. Rocha V., Labopin M., Sanz G., et al. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med 351 (2004) 2276-2285
146. Eapen M., Rubinstein P., Zhang M., et al. Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study. Lancet 369 (2007) 1947-1954
147. Dhedin N., Dombret H., Thomas X., et al. Autologous stem cell transplantation in adults with acute lymphoblastic leukemia in first complete remission: analysis of the LALA-85, -87 and -94 trials. Leukemia 20 (2006) 336-344
148. Toyoda Y., Manabe A., Tsuchida M., et al. Six months of maintenance chemotherapy after intensified treatment for acute lymphoblastic leukemia of childhood. J Clin Oncol 18 (2000) 1508-1516
149. Jacobs S., Stork L., Bostrom B., et al. Substitution of oral and intravenous thioguanine for mercaptopurine in a treatment regimen for children with standard risk acute lymphoblastic leukemia: a collaborative Children's Oncology Group/National Cancer Institute pilot trial (CCG-1942). Pediatr Blood Cancer 49 (2007) 250-255
150. Harms D., Gobel U., Spaar H., et al. Thioguanine offers no advantage over mercaptopurine in maintenance treatment of childhood ALL: results of the randomized trial COALL-92. Blood 102 (2003) 2736-2740
151. Stork L., Sather H., Hutchinson R., et al. Comparison of mercaptopurine (MP) with thioguanine (TG) and IT methotrexate (ITM) with IT "triples" (ITT) in children with SR-ALL: results of CCG-1952. Blood 100 (2002) 156a
152. Vora A., Mitchell C., Lennard L., et al. Toxicity and efficacy of 6-thioguanine versus 6-mercaptopurine in childhood lymphoblastic leukaemia: a randomised trial. Lancet 368 (2006) 1339-1348
153. Lennard L., Richards S., Cartwright C., et al. The thiopurine methyltransferase genetic polymorphism is associated with thioguanine-related veno-occlusive disease of the liver in children with acute lymphoblastic leukemia. Clin Pharmacol Ther 80 (2006) 375-383
154. Conter V., Valsecchi M., Silvestri D., et al. Pulses of vincristine and dexamethasone in addition to intensive chemotherapy for children with intermediate-risk acute lymphoblastic leukaemia: a multicentre randomised trial. Lancet 369 (2007) 123-131
155. Hutchinson R., Gaynon P., Sather H., et al. Intensification of therapy for children with lower-risk acute lymphoblastic leukemia: long-term follow-up of patients treated on Children's Cancer Group Trial 1881. J Clin Oncol 21 (2003) 1790-1797
156. Gajjar A., Harrison P., Sandlund J., et al. Traumatic lumbar puncture at diagnosis adversely affects outcome in childhood acute lymphoblastic leukemia. Blood 96 (2000) 3381-3384
157. te Loo D., Kamps W., Van der Does-van den Berg A., Van Wering E., and de Graaf S. Prognostic significance of blasts in the cerebrospinal fluid without pleiocytosis or a traumatic lumbar puncture in children with acute lymphoblastic leukemia: the experience of the Dutch Childhood Oncology Group. J Clin Oncol 24 (2006) 2332-2336
158. Lazarus H., Richards S., Chopra R., et al. Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII/ECOG E2993. Blood 108 (2006) 465-472
159. Pui C., Cheng C., Leung W., et al. Extended follow-up of long-term survivors of childhood acute lymphoblastic leukemia. N Engl J Med 349 (2003) 640-649
160. Hijiya N., Hudson M., Lensing S., et al. Cumulative incidence of secondary neoplasms as a first event after childhood acute lymphoblastic leukemia. JAMA 297 (2007) 1207-1215
161. Barredo J., Devidas M., Lauer S., et al. Isolated CNS relapse of acute lymphoblastic leukemia treated with intensive systemic chemotherapy and delayed CNS radiation: a pediatric oncology group study. J Clin Oncol 24 (2006) 3142-3149
162. Pui C. Toward optimal central nervous system-directed treatment in childhood acute lymphoblastic leukemia. J Clin Oncol 21 (2003) 179-181
163. Matloub Y., Lindemulder S., Gaynon P., et al. Intrathecal triple therapy decreases central nervous system relapse but fails to improve event-free survival when compared with intrathecal methotrexate: results of the Children's Cancer Group (CCG) 1952 study for standard-risk acute lymphoblastic leukemia, reported by the Children's Oncology Group. Blood 108 (2006) 1165-1173
164. Pui C., and Jeha S. New therapeutic strategies for the treatment of acute lymphoblastic leukaemia. Nat Rev Drug Discov 6 (2007) 149-165
165. Burgess M., Skaggs B., Shah N., Lee F., and Sawyers C. Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance. Proc Natl Acad Sci U S A 102 (2005) 3395-3400
166. van Es J., van Gijn M., Riccio O., et al. Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature 435 (2005) 959-963
167. Jordan C., Guzman M., and Noble M. Cancer stem cells. N Engl J Med 355 (2006) 1253-1261
168. Krivtsov A., Twomey D., Feng Z., et al. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature 442 (2006) 818-822
169. Krause D., Lazarides K., von Andrian U., and van Etten R. Requirement for CD44 in homing and engraftment of BCR-ABL-expressing leukemic stem cells. Nat Med 12 (2006) 1175-1180
170. Jin L., Hope K., Zhai Q., Smadja-Joffe F., and Dick J. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med 12 (2006) 1167-1174
171. Iwamoto S., Mihara K., Downing J., Pui C., and Campana D. Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase. J Clin Invest 117 (2007) 1049-1057